• Affiliate Professor, Global Health
  • Affiliate Professor, Medicine - Medical Genetics
  • HDT Bio Corp., CSO
  • CEO, PAI Life Sciences
  • CEO, Compliment Corp.

Seattle, WA 98102
United States

Phone Number: 
Select from the following:

Dr. Darrick Carter, HDT Bio’s founding CSO, is a biochemist/biophysicist with over 20 years of biotechnology experience most recently serving as CEO of PAI Life Sciences and VP of Adjuvant Technologies at IDRI. He has founded five companies beginning with an internet startup. At Corixa he led a new tuberculosis vaccine into human trials. He started PAI as a bioinformatics company using proprietary artificial neural nets. He helped spin out Dharma Therapeutics a specialty pharma company for drug delivery. Next, he co-founded a company improving cancer outcomes, Compliment Corp. He is an inventor on over 120 patents and applications with more than 80 publications co-authored.

  • PhD (Oregon Health & Science University)
  • BS (Oregon State University)
  • German
Health Topics 
  • Biodefense Infectious Diseases
  • Bioengineering
  • Cancer
  • Cervical Cancer
  • COVID-19
  • Drug and Vaccine Development
  • Ebola
  • Hepatitis
  • HPV
  • Immunizations
  • Infectious Diseases
  • Infectious Diseases (other than STDs)
  • Influenza
  • Informatics
  • Innate Immunity
  • Leishmaniasis
  • Malaria
  • Molecular Immunology
  • Neglected Diseases, Tropical Medicine (incl. Parasites)
  • TB
  • Viruses
DGH Centers, Programs and Initiatives and Affiliated Organizations 

Molehin AJ, Gray SA, Turner C, Davis J, Zhang W, Khatoon S, Rattan M, Kernen R, Peterson C, Sennoune SR, Carter D, Siddiqui AA. Process Development of Sj-p80: A Low-Cost Transmission-Blocking Veterinary Vaccine for Asiatic Schistosomiasis. Front Immunol. 2021 Feb 23;11:578715. doi: 10.3389/fimmu.2020.578715. PMID: 33732227; PMCID: PMC7959798.

Erasmus JH, Khandhar AP, O’Connor MA, Walls AC, Hemann EA, Murapa P, Archer J, Leventhal S, Fuller JT, Lewis TB, Draves KE, Randall S, Guerriero KA, Duthie MS, Carter D, Reed SG, Hawman DW, Feldmann H, Gale M, Veesler D, Berglund P, Heydenburg Fuller D. An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Science translational medicine. 2020:eabc9396. doi: 10.1126/scitranslmed.abc9396.

Zhang W, Le L, Ahmad G, Molehin AJ, Siddiqui AJ, Torben W, Karmakar S, Rojo JU, Sennoune S, Lazarus S, Khatoon S, Freeborn J, Sudduth J, Rezk AF, Carey D, Wolf RF, Papin JF, Damian R, Gray SA, Marks F, Carter D, Siddiqui AA. “Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer Protection in vivo and in vitro From Schistosoma mansoni and Identification of Putative Correlative Markers of Protection.” Frontiers in Immunology. 2020;11(1246). doi: 10.3389/fimmu.2020.01246.

Cookenham T, Lanzer KG, Gage E, Lorenzo EC, Carter D, Coler RN, Baldwin SL, Haynes L, Reiley WW, Blackman MA. Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity. Vaccine. 2020. doi: https://doi.org/10.1016/j.vaccine.2020.05.085.

Pitner RA, Durham PG, Stewart IE, Reed SG, Cassell GH, Hickey AJ, Carter D. “A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy”. Journal of pharmaceutical sciences, 2019. 108(10), 3302–3311. https://doi.org/10.1016/j.xphs.2019.05.024